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In June of 1981 an astute worker at the Centers for Disease Control 
(CDC) observed a new pattern of disease. In the previous eight months, 
physicians had suddenly made five requests for an experimental drug which 
had only been requested twice before between 1967 and 1979 for use in adults. 
Dispensed only by the CDC and used to treat an exceedingly rare infection, the 
drug was pentamadine isethionate. The infectious agent was Pneumocystis 
carinii. 
About the same time, reports began to flow into the CDC detailing the 
rise in incidence of another rare disease, a form of cancer called Kaposi's 
sarcoma. Simultaneously, and sometimes in association with the 
pneumocystis or kaposi's cases, the CDC noted a rise in chronic 
lymphadenopathy and diffuse, undifferentiated, non-Hodgkin's lymphoma. 
It was remarkable that all of these conditions had previously been found 
primarily in immunocompromised hosts. It was also notable that the vast 
majority of early cases were diagnosed in young homosexual men clustered 
around New York City, Los Angeles and San Francisco. By 1982, based on 
these epidemiological findings, the syndrome had been given a name, 
acquired immunodeficiency syndrome, or AIDS. 
Initially described in homosexuals, AIDS was soon found to affect 
other segments of the population. In 1982 AIDS was described in 
hemophiliacs, other blood-transfusion recipients, and intravenous drug users 
(IVDU's) who had shared needles with other users. By January of 1983 there 
were two well-documented cases of AIDS in heterosexual partners of IVDU's, 
making it clear that AIDS could be transmitted by heterosexual as well as 
homosexual contact. In late 1983, the HIV-1 virus was isolated and soon 
afterwards serological testing for HIV-1 became available.1 
\ 
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While the majority of early AIDS cases occurred in homosexual men, 
there has been an alarming rise in the percentage of cases attributable to 
intravenous drug use. In the U.S, 19% of AIDS cases from 1985 to 1987 were 
associated with intravenous drug use; however, this figure had climbed to 
26% by 1988.2 In Europe, the trends have been even more dramatic. 
Associated with only 2% of AIDS cases in 1983, intravenous drug use was 
responsible for an estimated 15% in 1985 and 34% in 1988. By the end of 1989, 
the year's newly diagnosed AIDS cases in IVDU's would exceed those in 
homosexuals.2 These increasing percentages are reflected in the significantly 
shorter doubling times of AIDS cases in IVDU's compared to homosexual 
AIDS cases. For example, in Europe, the time between the doubling of the 
number of AIDS patients from 1983 to 1985 was 4.4 months for IVDU's and 
8.8 months for homosexuals. In 1986 to 1988 it was 10.8 months and 20.4 
months respectively. 
AIDS among IVDU's is not limited to the developed world. There 
have been a rise in reported cases from South America (Brazil), Africa, Asia 
(Thailand), and Eastern Europe.2 It has been shown that the spread of AIDS 
among IVDU's can be quite rapid. In Manhattan, historically collected sera 
from IVDU's showed seroprevalence rising to >40% within three years after 
the first seropositive sample was collected.^ Edinburgh had an even more 
dramatic rise to 50% only two years after the first seropositive sample.^ In 
Bangkok, seroprevalence was measured at 0% in 1987 and 30% in 1988.2 
AIDS in IVDU's is also associated with spread to the heterosexual and 
pediatric populations. In 1988, 55% of AIDS cases associated with 
heterosexual transmission in the U.S. were partners of IVDU's. Seventy 
percent of pediatric AIDS cases were born to parents who were IVDU's or 
partners of IVDU's.2 There are an estimated 1.1 to 1.3 million IVDU's in the 
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U.S.5 Thus by the late 1980’s it was clear that AIDS among IVDU's was a 
major public health problem. It was international in scope and increasing at 
an alarming rate both within the intravenous drug using community and in 
heterosexual and pediatric populations as well. 
Nowhere is AIDS among IVDU's more of a problem than in the North 
Eastern region of the United States. In Connecticut the demographics of 
AIDS are skewed significantly from those of the country at large. While 59% 
of reported AIDS cases nationally are gay/bisexual men, in Connecticut only 
31% of AIDS cases occur in this population. Conversely IVDU's constitute 
47% of Connecticut cases as compared to 26% nationally. These statistics are 
even more skewed in the city of New Haven. The spread of AIDS to women 
and children in New Haven reflects these demographics. In New Haven, 
28% of adult cases are women compared to 10% nationally, and one third of 
the state's pediatric AIDS cases are from New Haven.6 
As these alarming figures and trends became evident, community 
leaders, public health workers, and legislators in Connecticut sought ways to 
address the epidemic of AIDS in IVDU's. In 1987 the New Haven Mayor's 
Task Force on AIDS was formed in order to develop a comprehensive 
strategy to break the connection between AIDS and intravenous drug use. In 
October, 1987, the Task Force went to work. Multicultural indigenous 
workers delivered AIDS information to addicts in areas of concentrated drug 
activity, helped users enter treatment programs and distributed condoms and 
"safety kits" filled with bleach and water to clean injection equipment. At the 
same time, the Task Force began to raise consciousness about the need for 
access to clean needles and to build support to legalize needle exchange 
programs (NEP's). A first step was to interview drug users about their 
injection behavior. IVDU's reported that they did not share needles as a 
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ritual of the drug culture as some had believed. Rather, they feared arrest for 
the possession of needles/syringes.6 Furthermore, access to clean needles was 
limited due to scarcity and cost. On the basis of these findings and the 
alarming scope of the AIDS problem among IVDU's the Task Force in 1989 
proposed a NEP before the Public health Committee of the Connecticut 
General Assembly. 
While there have been no controlled trials to show that NEP's are 
effective in curbing the transmission of HIV-1 among IVDU's/ there is good 
theoretical and circumstantial evidence to support this assertion. The 
theoretical evidence comes from epidemiological studies of intravenous drug 
using populations when stratified by injection behavior. A number of 
studies have shown that HIV-1 antibody seroprevalence rises with self- 
reported sharing of neediest 8-11 a more detailed study of IVDU's in New 
York City shows that the seroprevalence rises with the percent of total 
injections in shooting galleries, the percent of total injections with used 
needles, and the percent of total injections with needles shared with strangers 
or acquaintances.^ Finally, a study of IVDU's in Baltimore showed an HIV- 
1 seroprevalence of 9.8% in diabetic IVDU's compared to 24.3% in non¬ 
diabetics. The investigators conclude that the ready access to sterile 
needle/syringes among the diabetics has a protective effect obviating the need 
for sharing among drug users/ Thus, there is ample theoretical evidence to 
suggest that a NEP, by providing sterile injection equipment and reducing the 
need for needle sharing, would decrease the transmission of HIV-1 virus 
among IVDU's. 
Other evidence comes directly from experience with NEP's. There are 
a number of reports documenting diminished high-risk behavior in 
populations served by NEP's. Researchers affiliated with NEP's in the UK, 
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Australia, Amsterdam, Rotterdam and Sweden have all documented 
reduction in self-reported needle-sharing within their programs' 
populations.^ Given the clear evidence that needle sharing is at the heart of 
HIV-1 transmission in these populations, it is reasonable to assume that such 
behavior modifications should reduce transmission of this virus. The few 
seroprevalence studies of NEP populations also support the effectiveness of 
such programs. In Amsterdam a NEP was instituted in 1985. In 1986, the 
seroprevalence of NEP participants was 33%. In 1987 and 1988 this figure 
remained stable at 32% while similar populations without NEP's rose to 
approximately 60%.2 Three years after the early institution of a NEP in Lund, 
in southern Sweden, the seroprevalence for HIV-1 remained 1% while 
similar Scandanavian populations without such programs approached 
60%.14 Thus there is good circumstantial as well as theoretical support for 
the assumption that NEP's reduce transmission of HIV-1. 
Nonetheless, the research to date is not conclusive. No study has 
shown a decrease in HIV-1 rates among populations served by a NEP. 
Further, most studies have been limited to testing seroprevalence in 
populations served by a NEP without testing the used needles directly. 
Without showing a decrease in the infectedness of needles used by program 
participants, it is impossible to make definite conclusions about the efficacy of 
such a program. 
Because of this lack of good evidence and concern about encouraging 
drug use, the Public Health Committee proved reluctant to establish a legal 
exchange. However, the following year, with mounting public and medical 
support for such a program, representatives Bill Dyson (New Haven) and Joe 
Grabarz (Bridgeport) introduced a bill calling for decriminalization of sale and 
possession of needle/syringes statewide and the institution and funding of 
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three NEP's in Connecticut cities with a high concentration of intravenous 
drug use and AIDS. In March of 1990 the Public Health Committee voted in 
favor of a compromise bill authorizing the funding of one demonstration 
NEP by a vote of 15-5. The bill was then passed by a majority of Connecticut 
legislators with a vote of 99-36 and was signed into law by Governor O'Neill 
effective July 1, 1990. 
The city chosen to institute Connecticut's first NEP was New Haven. 
The NEP law mandated that 1) the program should provide for anonymous 
free exchanges of needle/syringes with an equal exchange of new for used 
needles up to a cap of five per exchange, 2) all needle/syringes distributed be 
marked and checked for return rates, 3) the program was to simultaneously 
offer education about HIV-1 transmission and prevention and assist 
participants in obtaining drug treatment services. 
The program must also monitor 1) return rate of needle/syringes 
distributed, 2) behavioral change of program participants such as needle 
sharing and condom use, 3) program participation rates and success rates in 
initiating and completing drug treatment services, 4) the incidence of 
intravenous drug use to determine whether any change occurred as a result 
of the program. 
A final aspect of the program set it apart from other similar programs 
around the world. A syringe tracking and testing system was designed to 
directly evaluate the program's effect in reducing the spread of HIV-1 among 
IVDU's. To do this all syringes distributed are marked with a unique 
number. When conducting an exchange, NEP workers record the sequence 
numbers of the syringes, the code name of the participant receiving the 
syringes (every NEP participant must carry a card with his or her code name 
on it) and the date and location of the exchange. When syringes are returned 
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they are placed in a cannister with the code name, date and location. The 
cannisters are then taken to the laboratory where this information is recorded 
as well as the sequence numbers in each cannister. Finally, a sample of these 
needles must be tested for evidence of the HIV-1 virus. 
The results of these tests are then analyzed using statistical models 
developed by Edward Kaplan at the Yale School of Management. Essentially, 
these models use the initial prevalence of HIV-1 positive needles and a 
number of fixed variables to project what the expected seroprevalence of HIV- 
1 in needles would be over time were the program to have no effect. These 
projections can then be compared to actual observations to provide a 
quantitative assessment of the NEP’s effect on HIV-1 transmission. 
Central to this process of evaluation, then, was the need for a 
dependable technique for detecting evidence of HIV-1 in needle/syringe 
combinations returned by IVDU's. This application represented a new 
frontier in HIV-1 testing and researchers at the Yale School of Medicine were 
asked for assistance. The special circumstances of this application required an 
extremely sensitive assay given the very small sample sizes (often less than 1 
microliter of dried blood). Ideally, the technique would also be specific, 
inexpensive, and easy to perform in large batches. In choosing a detection 
technique these investigators considered the five general classes of HIV-1 
assay. These include testing for the virus itself, viral antigens, viral RNA, 
human antibodies to the virus or human white cell HIV-1 proviral DNA. 
Culturing for virus directly was excluded on the grounds that it would 
be extremely labor intensive for such a large number of samples (tens of 
thousands). Furthermore, free virus tends to be present in relatively small 
copy numbers until late in infection.15 Testing for viral antigen was also 
excluded for this second reason. A third possibility was a polymerase chain 

reaction (PCR) assay using reverse transcriptase to amplify viral RNA. While 
in theory this test is the most sensitive available, it is both labor intensive 
and technically difficult and, therefore, inappropriate for such a large number 
of samples. 
Using an enzyme-linked immunosorbent assay (ELISA) was a fourth 
possibility. Commonly performed as a screening technique for blood donors 
or as the first diagnostic test in a clinic or hospital setting, the ELISA is a 
serological test to detect the presence of antibody to HIV-1 virus. There was 
little documentation of its use in such small samples (which were whole 
blood not sera) with the exception of one study done by investigators in 
Florida. These investigators collected used needle/syringe combinations 
from three shooting galleries in South Florida and tested for antibody using 
the Abbott ELISA. They found 15 of 148 needles (10.1%) tested positive. Of 
the needles with visible blood 20.0% were positive while only 5.1% without 
visible blood showed presence of antibody^. While these results were 
interesting, the Yale group noted that the seroprevalence in the IVDU's using 
these shooting galleries was reported at approximately 36%. They were 
concerned that the ELISA results must therefore be an unacceptably low 
estimate of the true infectedness of the gallery needles. This concern was 
bolstered by the fact that the ELISA was positive in only 5.1% of needles 
without visible blood. It appeared, at least from this study, that the ELISA 
might lack the sensitivity for such small samples. 
The final alternative was to use a PCR assay to amplify and detect HIV- 
1 proviral DNA in human white cells. By this time the ability of PCR to 
detect sequences from the HIV-1 genome in human white cells had been well 
described,^ although no one had attempted its application in this type of 
sample. The great strength of PCR is its ability to amplify a specific DNA 
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sequence in very small copy numbers (down to one molecule) into the 
millions and thereby allow its detection. The technique seemed ideally suited 
for this application and was therefore, chosen as the best alternative. 
It was at this stage, in November 1990, that I joined Dr. Edwin Cadman 
and Robert Heimer, Ph.D. as part of the laboratory research group responsible 
for testing returned needle/syringes. Initially involved in trying to develop 
the optimal PCR technique for detecting HIV-1 proviral DNA in needles, I 
became increasingly interested in the theoretical limitations of this assay and 
began to wonder if it really was the most appropriate technique for this 
application. 
Because HIV-1 proviral DNA is found almost exclusively in CD4+ 
cells,18 the sensitivity of PCR in testing a given volume of blood is 
proportional to the CD4 count/microliter multiplied by the concentration of 
proviral DNA in that patient's CD4 population. I was concerned that the 
sensitivity of the PCR assay would be limited by the relatively small copy 
number of HIV-1 proviral DNA sequences in a population of host CD4+ cells. 
I was further concerned that in HIV+ patients, as the CD4 count fell, detection 
of proviral DNA might be even more difficult. A number of studies have 
used the PCR to attempt to quantify the number of white cells required to 
detect a single copy of HIV-1 proviral DNA. Schnittman et al report 
approximately one copy of HIV-1 proviral DNA per 100 CD4+ cells in patients 
with AIDS. 18 A second study performed by Simmonds et al found there was 
one copy of HIV-1 proviral DNA in 108-9130 CD4 cells with fewer copies in 
less advanced disease.^ Donovan et al, however, found one copy of HIV-1 
proviral DNA per 10-200 peripheral blood mononuclear cells (PBMC’s) in six 
patients with AIDS.^O These experiments are consistent, then, with an 
♦ 
1 0 
infection rate that covers a range from approximately 1: 1-100 CD4 cells in 
symptomatic patients with AIDS. 
Most of the needles returned from the NEP contained less than one 
microliter of dried blood. In a healthy, HIV negative person one would 
expect approximately 500 CD4 cells in this volume. Thus, if we assume 500 
CD4 cells per sample ( a generous assumption in both the volume of blood 
and the CD4 count per microliter) we are close to the cutoff point where we 
would not expect to find a single molecule of HIV-1 proviral DNA. In fact, of 
the twelve patients studied by Simmonds, only four averaged one copy of 
proviral DNA in less than 600 CD4 cells.19 Furthermore, the vast majority of 
HIV+ NEP participants are presumably asymptomatic,or at least are not 
suffering full-blown AIDS. There is little literature on the proviral burden in 
asymptomatic patients. Simmonds cites unpublished data to give an 
estimate of one copy per 1,000-10,000 CD4 cells in such patients.19 Thus, 
while asymptomatic HIV+ patients are likely to have higher CD4 counts than 
AIDS patients, they are also likely to have a lower concentration of proviral 
DNA within their CD4 cell population. One could only speculate on the net 
effect of these opposed trends on the sensitivity of PCR. If higher CD4 counts 
outweighed lower proviral copy number, then PCR would be more sensitive 
in asymptomatic patients. However, the inverse is also possible. Given this 
arithmetic I became concerned that needles with small amounts of blood 
from HIV+ participants might routinely test negative by our techniques. 
From a practical standpoint, the PCR assay was labor intensive, time- 
consuming, and expensive, and switching to an ELISA would probably 
represent improvements in all these areas. 
In an initial experiment I found that the Abbott ELISA was sensitive 
enough to detect anti-HIV-1 antibody in as little as .02 microliters of dried 
I 
blood left overnight in a syringe in ten of ten known positive samples and as 
little as .002 microliters in eight of ten. Given these encouraging results, I 
designed an experiment to compare PCR with ELISA directly by using serial 
dilutions of known positive and negative blood. I would then correlate the 
results with the subjects' CD4 counts to see whether the sensitivity of PCR 
dropped off with falling CD4 counts. 
Materials and Methods 
We received approval for our protocol from the Human Investigations 
Committee. Twenty volunteers at the Nathan Smith Clinic (a clinic for 
HIV+ patients) donated four tubes of blood each. Five of these patients were 
asymptomatic, with CD4 counts of 500 or greater and not being treated with 
AZT or other antiretroviral agents. Two tubes of blood were used to measure 
T-cell counts, and one tube was used to prepare sera. Using the final tube, we 
prepared ten needle/syringes by drawing up five microliters of blood and 
leaving to dry for 24 hours. Additional samples were obtained from three 
HIV- volunteers from which sera and needle/syringes were prepared. We 
then used the PCR and ELISA assays to test serial dilutions from the extracts 
of these needles. Western blots were also performed on these specimens to 
determine the limits of sensitivity of this technique and its potential for 
application in confirming ELISA results. Finally, the PCR, ELISA, and 
western results were compared to each other and to the T-cell studies to 
determine which technique was most sensitive, whether the sensitivity of 
PCR was effected by a patient's T-cell profile, and whether there was a 
difference in sensitivities between symptomatic and asymptomatic HIV+ 
patients. 

T-cell Studies 
After phlebotomy of HIV+ volunteers, one tube of blood was sent 
directly to the hematology laboratory where complete blood count and 
manual differential were performed. A second tube was sent to the 
immunology laboratory where whole blood was incubated with a set of 
conjugated monoclonal antibodies to specific surface antigens. After 
incubation, the erythrocytes were lysed and removed. Fluorescein conjugated 
(green) anti-human leukocyte antibody (HLe-1) and phycoerythrin conjugated 
(red) anti-monocyte antibody (leu-M3) were used to separate 
polymorphonuclear cells, lymphocytes and monocytes electronically using 
flow cytometry. The lymphocytes were then divided by flow cytometry into B 
and T-lymphocyte subsets using green anti-CD3, red anti-CD4, green anti- 
CD20, and red anti-CD8 antibodies in the following combinations: 
green anti-CD3 and red anti-CD4 
cells that are both red and green are CD4+ T cells (helper inducer) 
green anti-CD3 and red anti-CD8 
cells that are both red and green are CD8+ T cells (suppressor/cytotoxic) 
green anti CD20 
cells that are green are CD20+ B cells 
Lymphocyte subset numbers were quantified by multiplying the percentage of 
lymphocytes which were positive for each subset against the number of 
lymphocytes per cubic mm of blood (hence the need for a complete blood 
count with differential). 
ELISA 
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Needles containing five microliters of HIV+ or HIV- blood were 
flushed 4-5 times with 50 microliters of normal saline to produce a solution 
which was concentrated at 10%. Four further dilutions were then prepared, 
resulting in 1.0%, 0.1%, 0.01%, and 0.001% solutions. Then 10 microliters of 
each of these five solutions were assayed by ELISA (Abbott Enzyme 
Immunoassay) using the standard protocol with the exception that the first 
dilution step was omitted. Ten microliters of these solutions contained 1.0, 
0.1, 0.01, 0.001, and 0.0001 microliters of blood respectively. The Abbott ELISA 
is manufactured by propagating HIV-1 in a T-lymphocyte cell line 
H9/HTLVIIIB- Isolated virus is then disrupted and inactivated with 
detergent and sonification. Two major viral proteins are purified from the 
lysate, and a combination of whole lysate and purified viral proteins is coated 
onto beads. In testing for HIV-1, these beads are then incubated with the 
sample being tested, and any anti-HIV-1 antibody in the sample binds to the 
HIV-1 antigens on the solid phase. The beads are then washed to remove 
unbound material. The beads are then incubated with goat anti-human IgG 
antibody conjugated with horseradish peroxidase. This antibody binds to 
human antibody bound to the beads. After washing off unbound enzyme, a 
hydrogen peroxide containing solution, with o-Phenylenediamine as 
substrate, is added and a yellow-orange color develops in proportion to the 
amount of HIV-1 antibody bound to the beads. The absorbence of this 
solution is read spectrophotometrically and compared to known positive and 
negative controls to determine positivity.21 
Western Blots 
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After performing the ELISA, western blots were done on enough 
dilutions from each patient to provide a range from positive to negative in 
order to define the limits of sensitivity of this technique. The Bio-Rad 
NovopathTM HIV-1 Immunoblot assay was used. This kit is manufactured 
by propagating HIV-1 in a HUT-78 T-lymphocyte cell line. Partially purified 
virus is then inactivated and disrupted by treatment with sodium dodecyl 
sulfate (SDS). Specific HIV-1 proteins are then separated according to 
molecular weight by gel electrophoresis in the presence of SDS. These 
separated proteins are then transferred by electroblotting onto a sheet of 
nitrocellulose which is then washed and cut into strips. Sample is incubated 
with these strips and then washed. Next a goat anti-human IgG antibody 
conjugated to alkaline phosphatase (AP) is incubated with the strips and 
binds to human anti-HIV-1 antibody bound to the strips. Finally, after 
washing off unbound enzyme, AP substrate solution containing 5-bromo, 4- 
chloro, 3-indolyl phosphate/ nitro blue tetrazolium is added such that bands 
appear corresponding to the position of the following HIV-1 proteins (p) or 
glycoproteins (gp): pl8, p24, p32, gp41-43, p51, p55, p65, gpl20, and gpl60. The 
pattern of bands was then interpreted as negative, indeterminate or positive. 
A positive test exhibited reactivity to at least one major product of each of the 
structural genes: GAG (p55, p24, or pi8), ENV (gpl60, gpl20, or gp41), and POL 
(p65, p51, or p32). A negative test showed no reactive bands, and an 
indeterminate test was anything in between.22 
PCR 
Preparation 
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In order to test for the presence of HIV-1 proviral DNA, syringe/needle 
combinations were first flushed 4-5 times with 100 microliters of a buffer 
containing 10 mM Tris-HCL, pH 8.3, 50 mM KCL, 2.5 mM MgCl2, 0.5% Tween 
20, 0.5% NP-40, 60 micrograms/ml proteinase K. Four subsequent ten-fold 
dilutions were then made from this extraction solution. These extracts were 
digested either for 1 hour at 60 degrees C, inactivated by incubation at 95 
degrees C for 15 min, and stored at 4 degrees C. DNA was additionally 
purified by extraction first with Tris-buffered phenol and then with 
cloroform/isoamyl alcohol (24:1) and precipitation by addition of Na acetate 
and ethanol with 5 micrograms of yeast tRNA added as carrier. Precipitates 
were stored at -20 degrees C and pelleted and dried prior to use in PCR. The 
samples then tested contained the equivalent of 4.5, 0.45, 0.045, 0.0045, and 
0.00045 microliters of blood. 
Amplification 
A previous series of experiments had shown improved sensitivity of 
PCR using a double round of amplification with nested primers—fifteen cycles 
using gag816/1097 (the notation here refers to the 281 base-pair(BP) sequence 
found between BP number 816 and 1097 on the structural gag gene of HIV-1) 
followed by 35 cycles using gag856/1046.23 The primers for the 816/1097 pair 
consisted of a 21 BP sequence ( GAAGGCTTTCAGCCCAGAAGT) at the 816 
end and a 21 BP sequence (GGTGGATTATTTGTCATCCAT) at the 1097 end. 
The primers for the 856/1046 pair were both 20 BP's in length, 
(TTATCAGAAGGAGCCACCCC) and (CCTGCTATGTCACTTCCCCT) 
respectively. Using this technique we were able to reproducibly detect HIV-1 
proviral DNA in dilutions with as few as two copies of a plasmid containing 
the HIV-1 genome.24 DNA to be amplified was resuspended in 20 microliters 
of TE-80 (10 mM Tris-HCL, pH 8.0,1 mM EDTA), maintained on ice, and 

included as part of 100 microliter reactions containing the target DNA, 10 mM 
Tris-HCL, pH 8.3, 50 mM KCL, 1.5 mM MgCl2,100 micrograms/ml gelatin, 
1.25 mM of each dNTP, 20 picomoles of the primer pair gag816/1097, and 2 U 
Taq polymerase. PCR commenced with denaturation of the DNA at 95 
degrees C for 2 min directly followed by 15 cycles of amplification in a 
Biosycler (Bios Corp., New Haven, CT.). A second round of amplification was 
then performed using 50 picomoles of each of the gag856/1046 primer pair in 
the same reagents plus 25 microliters of reaction mix from the first round. 
Following the final cycle, elongation was continued for 6 min. Primers and 
their associated probes were synthesized in house by the Yale Medical School 
nucleic acid chemistry facility. 
Detection 
PCR products were analyzed by electrophoresis and Southern blotting. 
Aliquots of 20 microliters from each reaction and, as size markers, 
pBR322/BstNI (New England Biolabs, Beverly, MA) were run on 2.5% 
agarose gels at 100mA using TAE buffer. DNA in gels was denatured using 
0.5 N NaOH, 1.5 M NaCl, neutralized using 0.5 M Tris-HCL, pH 7.2,1.5 M 
NaCl, transferred to Hybond-N nylon membranes (Amersham, Arlington 
Heights, IL), and crosslinked by 5 min shortwave UV exposure. Membranes 
were prehybridized with a solution containing 6X SSC (20X SSC is 0.3M 
NaCitrate and 3.0 M NaCl), 5X Denhardt's (0.1% Ficoll, 0.1% 
polyvinylpyrrolidone, 0.1% bovine serum albumin), 0.1% SDS, 100 
micrograms/ml sheared, denatured salmon sperm DNA for 4 hours at 65 
degrees C and, following removal of excess prehybridization buffer, 
hybridized for 16-20 hours at 70 degrees C using 10^ cpm of an appropriate 
[gamma-32p] ATP-kinased oligomer probe per ml of hybridization buffer (6X 
SSC, 5X Denhardt's, 100 micrograms/ml denatured salmon sperm DNA). 
V 1 
This probe was picked carefully to have a sequence specific to a region 
internal to both of the sets of primers used in the amplification so as to add 
an additional level of specificity to the detection process. It is a 23 BP 
fragment from gag 927 to 905 with the following sequence: 
GCATGGCTGCTTGATGTCCCCCC. Filters were washed with 6X SSC, 0.1% 
SDS three times at room temp for 5 min each and twice at 60 degrees C for 15 
min each. Amplified DNA was visualized using X-ray film exposed at -70 
degrees C in cassettes with intensifying screens. 
Results 
PCR vs. ELISA 
Both ELISA and PCR gave positive signals for the first dilution of all 
fifteen symptomatic patients and all five asymptomatic patients (sensitivity = 
100%). ELISA and PCR gave negative results for all the HIV- patients tested 
(specificity = 100%) [see Figure 1 a-d in Appendix B for photographs of PCR 
southern blots]. 
In every HIV+ patient, symptomatic or asymptomatic, the ELISA was 
able to detect positive signal at lower dilutions than PCR (see Table 1). In the 
symptomatic group the mean volume of blood below which ELISA became 
negative was 0.00086 microliters. This may, in fact, be falsely elevated as 
samples were not tested below 0.0001 microliters, and four of the fifteen 
samples were still positive at this dilution. The median was 0.001 microliters. 
In the same group, the mean volume of blood below which PCR 
became negative was 0.067 microliters and the median was 0.045 microliters. 

TABLE 1 
Minimum Volume of Blood Yielding 
Positive Detection of HIV-1 in Symptomatic Patients 
(in microliters) 
Patient # 
CD4+ cells/ 
microliter ELISA PCR Weste 
1 1 0 0.001 0.45 1 .0 
2 800 0.001 0.0045 0.1 
3 1 70 0.0001 * 0.45 0.1 
4 7 0 0.01 0.45 1.0 
5 3 0 0.01 0.45 sera 
6 420 0.001 0.0045 0.1 
7 370 0.0001 * 4.5 0.01 
8 1 0 0.01 4.5 sera 
9 5 0 0.001 0.0045 0.1 
1 0 2 0 0.0001 * 0.0045 0.1 
1 1 260 0.001 0.0045 0.1 
1 2 290 0.001 0.045 1.0 
1 3 2 0 0.001 0.045 0.1 
1 4 730 0.001 0.0045 1.0 
1 5 4 0 0.0001 * 0.045 0.1 
Geometric 
Mean: 0.00086 0.062 0.17 
Median: 0.001 0.045 
Dilutions below this level were not tested. 
Calculated by excluding patients 5 and 8. 

When this data is analyzed using a non-parametric two tailed sign test (which 
asks what is the probability that using two 
equally sensitive tests one test would be more sensitive than the other 15/15 
times) the p-value is <0.0001. The 95% confidence interval, using this 
technique is (0.0022 - 0.2222). In other words, one can say with 95% 
confidence that ELISA is between 5 and 500 times more sensitive than PCR in 
this group of patients. The same data may be analyzed using a paired, two 
tailed T test. Functionally, this test uses the null hypothesis that if both 
detection techniques are equally sensitive then the sum of the differences 
between the lowest PCR+ dilution and ELISA+ dilution for each subject 
would equal zero. This number is then calculated and the p-value reflects the 
credibility of the null hypothesis. Using this test the T value is -5.95, and p is 
= 0.0000. Graphically, this improved sensitivity of ELISA over PCR in the 
symptomatic patients is depicted in Figure 2. The number of patients still 
testing positive is graphed as a function of decreasing dilutions using a 
negative logarithmic scale. 
In the asymptomatic group the sample size is smaller, and one must be 
wary of making overly strong conclusions from a limited data pool. 
Nonetheless, the results suggest a clear trend (see Table 2). In all but one 
patient, ELISA was positive down to the last dilution while PCR lost signal, 
on average, at the second dilution. The mean threshold for detection by 
ELISA was 0.00016 microliters, while for PCR it was 0.45 microliters. Thus, in 
the asymptomatic group, the ELISA shows improved sensitivity while PCR's 
sensitivity appears diminished. No matter how strong the differences, it 
would not be possible to show statistical significance of the results using the 
sign test (because such a test does not take into account the 
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TABLE 2 
Minimum Volume of Blood Yielding 
Positive Detection in Asymptomatic Patients 
(in microliters) 
CD4+_cells/ 
Patient # microliter ELISA PCR Western 
2 0 500 0.0001 * 0.45 0.001 
2 1 1 090 0.001 0.45 1.0 
2 2 990 0.0001 * 0.45 0.01 
2 3 880 0.0001 * 0.045 0.01 
2 4 900 0.0001 * 4.5 0.001 
Geometric 
Mean: 0.00016 0.45 0.01 
Dilutions below this level were not tested. 
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magnitude of the differences between the two tests but only the number of 
times one test beats the other). However, when analyzed using the paired, 
two tailed T test the T value is -9.23 and p is < 0.0008. The 95% confidence 
interval is (0.000032 - 0.0039). Thus, in both the symptomatic and 
asymptomatic groups, ELISA remains sensitive at significantly lower 
dilutions than PCR. 
Western Blots 
The western blots proved uniformly less sensitive than the ELISA at 
detecting HIV-1 antibody in low concentrations. Of the twenty patients tested, 
there were no dilutions for which the western was positive and the ELISA 
negative. The mean threshold for detection by western was 0.17 microliters 
in the symptomatic group which was greater than both the ELISA and the 
PCR thresholds. In the asymptomatic group westerns performed somewhat 
better with a a threshold of 0.01 microliters which was lower than the PCR 
but at least two orders of magnitude less sensitive than the ELISA. 
T- Cell Studies 
The mean number of CD4 cells required in a solution for a positive 
signal by PCR was 5.4 among the symptomatic group (see Table 3). The range 
was from 0.09 to 76.5 with the exception of one outlier at 1,665. In 
interpreting the data from the two patients with values less than one, it is 
important to remember that these 
values represent probabilities. Obviously the true number of CD4 cells in a 
solution must be a whole number, presumably 1 in these cases. Among the 
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Table 3 
Threshold Number of CD4 Cells/Dilution Giving Positive 
Signal By ELISA and PCR 
(Symptomatic Patients) 
PCR ELISA CD4 cells/ 
Patient # resu It* result* microliter 
1 4.5 0.01 1 0 
2 3.6 0.8 800 
3 76.5 0.02 170 
4 31.5 0.7 7 0 
5 13.5 0.3 3 0 
6 1.8 0.4 420 
7 1 665.0 0.04 370 
8 45.0 0.1 1 0 
9 0.2 0.05 5 0 
1 0 0.09 0.002 2 0 
1 1 1.2 0.3 260 
1 2 13.7 0.3 290 
1 3 0.9 0.02 2 0 
1 4 3.3 0.7 730 
1 5 1.8 0.004 4 0 
Geometric 
Mean: 5.4 0.08 
* Estimated number of CD4 cells that would be found in the lowest dilution 
testing positive by these two techniques. 
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asymptomatic patients, the mean threshold CD4 count for detection by PCR 
was 379.6. The range was from 39.6 to 4050 CD4+ cells (see Table 4). 
Discussion 
PCR vs. ELISA 
It is difficult to make accurate estimates of the amount of blood 
remaining in a typical needle/syringe combination returned by a NEP 
participant. Approximately 30% of needles returned in the New Haven NEP 
have visible blood which correlates with a volume roughly > 0.5 microliters. 
In the symptomatic patient, the mean volume of blood required for a positive 
signal by PCR was 0.045 microliters, about one tenth of this volume. It seems 
credible, therefore, that within this subpopulation PCR would detect evidence 
of HIV in the majority of needles returned by HIV+ participants. In a few 
needles, with volumes below this level, ELISA might prove more sensitive. 
The asymptomatic patients pose more of a problem. In this group, the 
mean threshold below which PCR loses its sensitivity is 0.45 microliters of 
blood. Because this volume is quite close to the limit of visibility, one can 
assume that only approximately 30% of returned needles contain this much 
blood. These data would suggest that in testing needles from this 
subpopulation, the ELISA assay may 
offer a distinct advantage over PCR. This is especially important because the 
majority of HIV+ participants in a NEP are likely to be asymptomatic given 
the relatively short course from symptomatic AIDS to hospitalization and 
death compared to the much longer latent phase and the fact that 
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Table 4 
Threshold Number of CD4 Cells/Dilution Giving Positive 
Signal by ELISA and PCR 
(Asymptomatic Patients) 
PCR ELISA CD4 count/ 
Patient # result result microliter 
2 0 225.0 0.05 500 
2 1 490.5 1 .1 1 090 
2 2 4 4 5.5 0.1 990 
2 3 39.6 0.09 880 
2 4 4050.0 0.09 900 
Geometric 
Mean 379.6 0.13 
*Estimated number of CD4 cells that would be found in the lowest dilution 
testing positive by these two techniques. 
' 
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hospitalized patients do not participate in the NEP. Nonetheless, the sample 
size from this group is quite small, and the conclusions drawn from it must 
remain speculative until further data is gathered. 
One possibility that must also be considered is that the impressive 
sensitivity of the ELISA is not due to specific detection of anti-HIV-1 antibody 
but to non-specific binding of some other cross-reactive antibody. There have 
been reports of rare cases of false positive results with ELISA when this 
technique is used to screen large populations.25 One could postulate that 
IVDU's who are injecting foreign material and sharing needles may be 
exposed to a heavy non-self antigen load and therefore produce a large 
number of uncommon antibodies. It would be interesting, for this reason, to 
test the blood of known HIV- IVDU's by ELISA to see if there is any incidence 
of false positives. However, such an experiment was not within the scope of 
this study. A second way to evaluate this hypothesis is to compare the ELISA 
results to those from the western blots. Because western blot testing requires 
specific binding to at least three different HIV-1 antigens to be considered 
positive, it would presumably be less vulnerable to such non-specific cross¬ 
reacting antibodies. If, therefore, the ELISA were testing positive secondary to 
such contamination, one would not expect to see a similar trend in the 
western blots. However, in these experiments, there is a close relation 
between ELISA and western. In those patients in whom the ELISA is most 
sensitive, the western is most sensitive, and the inverse is also true. This is 
suggestive evidence, then, that a cross-reacting antibody is not playing a 
major role. It is important to note that the inferior sensitivity of PCR is not 
secondary to technical imperfections but to the biological principles upon 
which it is based. For a positive signal by PCR, there must be at least one 
molecule of HIV-1 proviral DNA. Controls were run with experimental 
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samples which routinely showed strong positives when only three copies of 
the HIV-1 genome were present. Presumably the dilutions below which PCR 
is negative but ELISA remains positive represent samples where there are no 
further infected CD4 cells present but there is still adequate antibody for 
detection by ELISA. 
Western Blot 
In both the symptomatic and asymptomatic patients, the western blot is 
approximately two orders of magnitude less sensitive than the ELISA. Given 
this disparity, western blots could not be used effectively to confirm ELISA in 
testing needles. While this lack of confirmation would be unacceptable in 
making individual diagnoses, it is less of a problem for this application. In 
testing needles, one follows trends of HIV positivity over "populations" of 
returned needles. While conceivably there may be some error at the level of 
individual tests, these errors should cancel out when large numbers of 
needles are compared at different time intervals. 
T-Cell Studies 
It has been previously discussed that positive signal by PCR depends on 
two factors: the concentration of HIV-1 proviral DNA within the CD4 
population and the number of CD4 cells in a sample. It appears that among 
the symptomatic patients, PCR's sensitivity is limited by this second factor 
with a mean threshold of detection of 5.4 cells. In the asymptomatic group, 
however, the number of CD4 cells fall in a range from 39.6 to 4,050, and the 
concentration of proviral DNA must be the limiting factor. The decreased 
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sensitivity of PCR in this population would suggest that the effect of lower 
copy numbers of proviral DNA outweighs the effect of concentration of CD4 
cells/microliter. Overall, the PCR results show an HIV-1 proviral copy 
number of approximately 1 per 1-75 CD4 cells (with the exception of one 
outlier from patient 7) in symptomatic patients and 1 per 40-4,000 in 
asymptomatic patients (again, the sample size here is quite small). These 
numbers are consistent with the copy numbers previously cited from the 
literature. 
Conclusion 
ELISA is a more sensitive technique than PCR for detection of HIV-1 
infection in small amounts of blood from needle/syringe combinations. This 
effect appears especially pronounced when testing needles from 
asymptomatic patients in whom the antibody concentration is high but the 
concentration of HIV-1 proviral DNA in the CD4 population is relatively 
low. The inferior sensitivity of PCR in this application is not secondary to 
technical imperfections but to the biological principles upon which it 
operates. 
Since the early 1980's, NEP's have been set up all over the world. To 
date there has been no proof that such programs diminish transmission of 
HIV-1 among IVDU's. To generate such proof requires documentation of 
decreasing infectedness of needles used by participants which, in turn, 
requires testing returned needles for evidence of HIV-1. This experiment 
suggests that both PCR and ELISA may be effective ways to do such testing. 
Paradoxically, it shows improved sensitivity using an ELISA. This is 
fortunate because it is a cheaper, easier, less technically demanding, and more 
■ , ' 
expeditious assay than is PCR. Its use should allow other programs around 
the world to evaluate their programs directly and make informed 
conclusions about their effectiveness. 

1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
30 
APPENDIX A 
Volume of 
blood in Symptomatic 
dilution (S) vs. CD4+ 
(in micro¬ asymptoma¬ PCR ELISA Western cells per 
liters) tic (A) result result result dilution 
sera S + 
4.5 S + 4 5 
1.0 S + + 1 0 
.45 S + 4.5 
0.1 S + +/- 1.0 
.045 S - 0.5 
.01 S + 0.1 
.0045 S - .05 
.001 S + .01 
.00045 S - .005 
.0001 S - .001 
sera S + 
4.5 S + 3600 
1.0 S + 800 
.45 S 360 
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2 . 1 S 
2 .045 S 
2 .01 S 
2 .0045 S 
2 .001 S 
2 .00045 S 
2 .0001 S 
+ +80 
+ 3 6 
+ + / - 8 
+ 3.6 
+ - .8 
. 4 
.08 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
sera S + 
4.5 S + 765 
1.0 S + 1 70 
.45 S + 76.5 
. 1 S + + 1 7 
.045 S - 7.7 
.01 S + - 1.7 
.0045 S - . 8 
.001 S + + / - . 2 
.00045 S - o
 
00
 
.0001 S + .02 
4 sera S 
4 4.5 S 
4 1.0 S 
4 .45 S 
4 .1 S 
4 .045 S 
.01 S 
+ 
+ 3 15 
+ +70 
+ 31.5 
+ - 7 
3.2 
. 7 4 + 
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4 .0045 S - . 3 
4 .001 S - - .07 
4 .00045 S - .03 
5 sera S + + 
5 4.5 S + 135 
5 1.0 S + + / - 3 0 
5 .45 S + 13.5 
5 . 1 S + - 3 
5 .045 S - 1.4 
5 .01 S + - . 3 
5 .0045 S - . 1 
5 .001 S - - .03 
5 .00045 S - .01 
6 se ra S + 
6 4.5 S + 1 790 
6 1 .0 S + 420 
6 .45 S + 179 
6 . 1 S + + 4 2 
6 .045 s + 17.9 
6 .01 s + + / - 4.2 
6 .0045 s + 1.8 
6 .001 s + - . 4 
6 .00045 s - . 2 
6 .0001 s .04 
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7 sera S + 
7 4.5 S + 1 665 
7 1.0 s + 370 
7 .45 s - 1 66.! 
7 . 1 s + + 3 7 
7 .045 s - 16.7 
7 .01 s + + 3.7 
7 .0045 s - 1.7 
7 .001 s + + / - . 4 
7 .00045 s - . 2 
7 .0001 s + .04 
8 sera s + + 
8 4.5 s + 4 5 
8 1.0 s + + / - 1 0 
8 .45 s - 4.5 
8 . 1 s + + / - 1.0 
8 .045 s - . 5 
8 .01 s + - . 1 
8 .0045 s - .05 
8 .001 s - - .01 
8 .00045 s - .005 
9 sera s + 
9 4.5 s + 225 
9 1 .0 s + 5 0 
9 .45 s + 22.5 
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9 . 1 S + + 5 
9 .045 S + 2.3 
9 .01 S + - . 5 
9 .0045 S + . 2 
9 .001 S + - .05 
9 .00045 S - .02 
9 .0001 S - .005 
1 0 sera S + 
1 0 4.5 S + 9 0 
1 0 1 .0 S + + 2 0 
1 0 .45 S + 9 
1 0 . 1 S + + 2 
1 0 .045 S + . 9 
1 0 .01 S + + / - . 2 
1 0 .0045 S + .09 
1 0 .001 S + - .02 
1 0 .00045 S - .009 
1 0 .0001 S + .002 
1 1 sera S + 
1 1 4.5 S + 1 170 
1 1 1.0 S + + 260 
1 1 .45 S + 1 1 7 
1 1 . 1 S + + 2 6 
1 1 .045 s + 1 1.7 
1 1 .01 s + _ 2.6 

1 1 
1 1 
1 1 
11 
1 2 
1 2 
1 2 
1 2 
1 2 
1 2 
1 2 
1 2 
1 2 
1 2 
1 2 
1 3 
1 3 
1 3 
1 3 
1 3 
1 3 
1 3 
1 3 
1 3 
1 3 
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.0045 S + 1 .2 
.001 S + - . 3 
.00045 S - . 1 
.0001 S - .03 
se ra S + 
4.5 S + 1365 
1.0 S + + 290 
.45 S + 1 36.J 
. 1 S + + / - 2 9 
.045 S + 13.7 
.01 S + + / - 2.9 
.0045 S - 1.4 
.001 S + - . 3 
.00045 S - . 1 
.0001 S - .03 
se ra S + 
4.5 S + 9 0 
1.0 S + + 2 0 
U)
 S + 9 
. 1 s + + 2 
.045 s + . 9 
.01 s + - . 2 
.0045 s - o
 
<0
 
.001 s + - 
CM
 
O
 
.00045 s .009 

1 3 
1 4 
1 4 
1 4 
1 4 
1 4 
1 4 
1 4 
1 4 
1 4 
1 4 
1 4 
1 5 
1 5 
1 5 
1 5 
1 5 
1 5 
1 5 
1 5 
1 5 
1 5 
1 5 
2 0 
36 
.0001 s .002 
sera S 
4.5 S 
1.0 S 
.45 S 
. 1 S 
.045 S 
.01 S 
.0045 S 
.001 S 
.00045 S 
.0001 S 
+ 
+ 3285 
+ + 730 
+ 328.5 
+ +/- 73 
+ 32.9 
+ - 7.3 
+ 3.3 
+ - .7 
. 3 
.07 
sera S 
4.5 S 
1.0 S 
.45 S 
. 1 S 
.045 S 
.01 S 
.0045 S 
.001 S 
.00045 S 
.0001 S 
+ 
+ 1 80 
+ +40 
+ 1 8 
+ +4 
+ 1.8 
+ +/ - .4 
. 2 
+ - .04 
.02 
+ .004 
sera A + 
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2 0 4.5 A + 2250 
2 0 1.0 A + + 500 
2 0 .45 A + 225 
2 0 . 1 A + + 5 0 
2 0 .045 A - 22.5 
2 0 .01 A + + 5 
2 0 .0045 A - 2.3 
2 0 .001 A + + . 5 
2 0 .00045 A - . 2 
2 0 .0001 A + + / - 
in
 
o
 
2 1 sera A + 
2 1 4.5 A + 4905 
2 1 1 .0 A + + 1 090 
2 1 .45 A + 490.5 
2 1 . 1 A + + / - 109 
2 1 .045 A - 49.1 
2 1 .01 A + + / - 10.9 
2 1 .0045 A - 4.9 
2 1 .001 A + - 1 .1 
2 1 .00045 A - . 5 
2 1 .0001 A - - . 1 
2 2 sera A + 
2 2 4.5 A + 4455 
2 2 1.0 A + + 990 
2 2 .45 A + 445.5 
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2 2 . 1 A + + 9 9 
2 2 .045 A - 44.6 
2 2 .01 A + + 9.9 
2 2 .0045 A - 4.5 
2 2 .001 A + + / - 1.0 
2 2 .00045 A - . 5 
2 2 .0001 A + - . 1 
2 3 sera A + 
2 3 4.5 A + 3960 
2 3 1.0 A + + 880 
2 3 .45 A + 396 
2 3 . 1 A + + 8 8 
2 3 .045 A + 39.6 
2 3 .01 A + + 8.8 
2 3 .0045 A - 4.0 
2 3 .001 A + + / - . 9 
2 3 .00045 A - . 4 
2 3 .0001 A + + / - .09 
2 4 sera A + 
2 4 4.5 A + 4050 
2 4 1.0 A + + 900 
2 4 .45 A - 405 
2 4 . 1 A + + 9 0 
2 4 .045 A - 40.5 
2 4 .01 A + + 9 
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2 4 .0045 A - 4.1 
2 4 .001 A + + . 9 
2 4 .00045 A - . 4 
2 4 .0001 A + + / - ..09 
Data from HIV- Patients 
Volume of blood in 
dilution (in PCR ELISA 
Patient # microliters) result resu It 
1 6 
1 6 
1 6 
sera 
4.5 
1 .0 
1 7 
1 7 
1 7 
sera 
4.5 
1 .0 
1 8 
1 8 
1 8 
sera 
4.5 
1.0 
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Appendix B 
(Figures la-d) 
Figures la-d show photographs of the southern blots showing 
PCR results for patients 1-24. Where there are patient numbers 
bracketing five rows, each row represents one of the five tested 
dilutions in decreasing order. The letter M stands for markers 
(kinase labelled pBR 322 digested with BstNI) used to identify 
whether the bands are appearing in the expected locations for 
sequences of their molecular weight. The negative controls include 
lanes with no DNA, K562 (a human erythroleukemia cell-line), HT 
1080 (a human epithelioid carcinoma), C6 (a mouse astrocytoma), and 
human white blood cell DNA from HIV- volunteers. These negative 
controls were run through the identical amplification and detection 
steps as the patient samples. pBHIO is a plasmid containing one 
copy of the HIV-1 genome. The letters A, B, and C correspond to 3.5, 
35, and 350 copies of this plasmid in the dilution tested. In Figure 
1b, lane D corresponds to 2 microliters of white blood cell DNA 
extracted from an HIV+ patient. This volume would contain 
approximately 5,000-6,000 cell equivalents. In Figure Id, lane D is 
the same as in Figure 1b, and lane E is a tenfold dilution of lane D 
(containing 500-600 cell equivalents). Finally, in Figure 1b, the 
lanes marked HIV- needles correspond to patients 16, 17, and 18, the 
HIV- volunteers. 
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